Presenting Author:

Kristina Doytcheva, M.S.

Principal Investigator:

Beatrice Nardone

Department:

Dermatology

Keywords:

hepatitis B, Hepatitis C, psoriasis, chronic hepatitis

Location:

Ryan Family Atrium, Robert H. Lurie Medical Research Center

C15 - Clinical

Prevalence of Chronic Hepatitis in Psoriasis Patients

Introduction Hepatitis (B and C) is an important determinant, especially with biologic agents for psoriasis, presumably related to the potential for reactivation of Hepatitis B. However, reports on prevalence are inconsistent. The aim of this study was to determine the prevalence of hepatitis (B and C) in psoriasis patients in a large single center, U.S patient population by searching an EMR data repository. Methods The study cohort consisted of all adults aged 18-89 years who underwent hepatitis B or C serology screening (September 2010 through September 2016). Psoriasis and hepatitis diagnoses were identified by ICD Codes (ICD9 and ICD10 codes: 696.1, L40.0-L40.4, L40.8, L40.9 and base code B18, B19, 070, respectively). The control cohort consisted of all patients within the same database with no psoriasis diagnosis. Statistical analysis was performed using logistic regression, from which crude and adjusted (for age, gender, and race) analyses were calculated. Results A total of 114,860 patients (57.6% female, 49.7% Caucasian) underwent hepatitis (B and/or C) screening. Of 2,591 patients with psoriasis, 48 (1.8%) had positivity for hepatitis (B and/or C) compared to 2,775 (2.5%) patients in the non-psoriasis cohort (n=112,269). Prevalence of hepatitis (B and C) was significantly lower in psoriasis compared to non-psoriasis cohort, both in the crude and adjusted analyses (crude OR=0.745, 95% CI = 0.558-0.993, p=0.045; adjusted OR=0.664, 95% CI = 0.497-0.888, p=0.006). Conclusions These findings of lower prevalence for chronic hepatitis (B and C) in this study population warrant further exploration to determine clinical significance for these findings in the management of psoriasis.